BACKGROUND & AIMS: A better understanding of the immunomodulatory effects of
PegIFNα therapy could allow more rational optimisation of future therapeutic approaches in …

IFN-lambda (IFNλ) is a member of the type III IFN family and is reported to possess anti-
pathogen, anti-cancer, and immunomodulatory properties; however, there are limited data …

Background & Aims Pegylated interferon-alpha (PegIFNα) remains an attractive treatment
option for chronic hepatitis B virus (HBV) infection because it induces higher rates of antigen …

Background & Aims The interaction between HBV replication and immune modulatory
effects mediated by IFNα therapy is not well understood. We characterized the impact of …

BACKGROUND & AIMS: The effect of IFN-α therapy on HBV-specific T-cell responses in
HBeAg-negative, genotype D, chronic hepatitis B is largely undefined. Understanding to …

Patients with chronic hepatitis B (CHB) undergoing interferon (IFN)-α-based therapies often
exhibit a poor HBeAg serological response. Thus, there is an unmet need for new therapies …

NK cells are important antiviral effectors, highly enriched in the liver, with the potential to
regulate immunopathogenesis in persistent viral infections. Here we examined whether …

Hepatitis B virus (HBV) and hepatitis C virus (HCV) cause a large proportion of acute and
chronic liver disease worldwide. Over the past decades many immunological studies …

Chronic hepatitis B virus (HBV) infection remains a major challenge for clinicians, as there
are only two types of approved therapies: interferon-alpha (IFN-α) or its pegylated form, Peg …

Background & Aims Hepatitis B virus (HBV) persistence and the pathobiology of chronic
HBV (CHB) infections result from the interplay between viral replication and host immune …